e-learning
resources
Vienna 2012
Monday, 03.09.2012
Viral infections and rare respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Limited effect of clarithromycin in non-elderly, non-severe patients with influenza
H. Ishii, K. Komiya, H. Kushima, H. Oka, H. Mukae, J.I. Kadota (Yufu, Kitakyushu, Japan)
Source:
Annual Congress 2012 - Viral infections and rare respiratory infections
Session:
Viral infections and rare respiratory infections
Session type:
Thematic Poster Session
Number:
2535
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Ishii, K. Komiya, H. Kushima, H. Oka, H. Mukae, J.I. Kadota (Yufu, Kitakyushu, Japan). Limited effect of clarithromycin in non-elderly, non-severe patients with influenza. Eur Respir J 2012; 40: Suppl. 56, 2535
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Combination of nitazoxanide with oseltamivir compared with oseltamivir in hospitalized patients with influenza
Source: Virtual Congress 2020 – Respiratory viruses in the "pre COVID-19" era
Year: 2020
Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin
Source: Eur Respir J 2001; 18: Suppl. 33, 542s
Year: 2001
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma
Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues
Year: 2015
Duration of therapy in hospitalised patients with CAP
Source: Annual Congress 2007 - An international perspective of the management of hospitalised patients with community-acquired pneumonia
Year: 2007
Six months azithromycin treatment in COPD patients with high risk of further exacerbations
Source: International Congress 2017 – Management of COPD
Year: 2017
Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors
Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD
Year: 2003
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004)
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 194s
Year: 2007
Efficacy of influenza and pneumococcal vaccinations among patients with COPD
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007
Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France
Source: Eur Respir J 2003; 22: Suppl. 45, 151s
Year: 2003
Comparison of efficacy of grippe vaccination in asthma and COPD patients
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Timing of previous hospitalizations impacts outcomes in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia
Year: 2009
Effect of roflumilast on hospitalizations in COPD patients
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Differences between asthmatics and nonasthmatics hospitalised with influenza A infection
Source: Eur Respir J 2013; 41: 824-831
Year: 2013
Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept